Mipet Meloxaid (NF) Oral Susp Cat 5ml
Meloxaid 0.5 mg/ml oral suspension for cats
Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures in cats, e.g. orthopaedic and soft tissue surgery. Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders in cats.
Oral use.
Post-operative pain and inflammation following surgical procedures:
After initial treatment with a suitable 5 mg/ml meloxicam solution for injection for cats,
continue treatment 24 hours later with Meloxaid 0.5 mg/ml oral suspension for cats at
a dosage of 0.05 mg meloxicam/kg body weight (0.1 ml /kg). The oral follow-up dose
may be administered once daily (at 24-hour intervals) for up to four days.
Acute musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight (0.4 ml/kg)
on the first day. Treatment is to be continued once daily by oral administration (at 24-
hour intervals) at a dose of 0.05 mg meloxicam/kg body weight (0.1 ml /kg) for as
long as acute pain and inflammation persist.
Chronic musculo-skeletal disorders:
Initial treatment is a single oral dose of 0.1 mg meloxicam/kg body weight (0.2 ml/kg)
on the first day. Treatment is to be continued once daily by oral administration (at 24-
hour intervals) at a maintenance dose of 0.05 mg meloxicam/kg body weight (0.1 ml
/kg). A clinical response is normally seen within 7 days. Treatment should be
discontinued after 14 days at the latest if no clinical improvement is apparent.
Route and method of administration
A one ml syringe is provided with the product. To be administered orally either mixed
with food or directly into the mouth. Particular care should be taken with regard to the
accuracy of dosing. The recommended dose should not be exceeded.
Advice on correct administration
Shake well before use.
Avoid introduction of contamination during use.
One ml contains:
Active substance
Meloxicam 0.5 mg
Excipient
Sodium benzoate 1.5 mg
List of excipients
Sodium benzoate
Glycerol
Citric acid monohydrate
Xanthan gum
Povidone
Sodium dihydrogen phosphate monohydrate
Simethicone emulsion
Honey flavour
Silica, colloidal anhydrous
Water, purified
Special precautions for use in animals
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a
potential risk of renal toxicity.
Post-operative use:
In case additional pain relief is required, multimodal pain therapy should be
considered.
Chronic musculoskeletal disorders:
Response to long-term therapy should be monitored at regular intervals by a
veterinary surgeon.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
People with known hypersensitivity to non-steroidal anti-Inflammatory drugs
(NSAIDs) should avoid contact with the veterinary medicinal product.
Accidental ingestion of the product by a child may cause gastro-intestinal effects,
such as nausea and gastric pain.
Any uneaten medicated food must be disposed of immediately and the bowl washed
thoroughly.
Do not leave an unattended filled syringe in the sight or reach of children.
In case of accidental ingestion, seek medical advice immediately and show the
package leaflet or the label to the physician.
This product can cause eye irritation. In case of contact with the eyes, immediately
rinse thoroughly with water.
Adverse reactions (frequency and seriousness)
In cats, typical adverse reactions of NSAIDs such as loss of appetite, vomiting,
diarrhoea, faecal occult blood, lethargy and renal failure have very rarely been
reported. Gastrointestinal ulceration and elevated liver enzymes were reported in
very rare cases.
These side effects are in most cases transient and disappear following termination of
the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a
veterinarian should be sought.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated
reports).
Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during
pregnancy and lactation (see section 4.3).
Interaction with other medicinal products and other forms of interaction
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances
with high protein binding may compete for binding and thus lead to toxic effects.
Meloxaid must not be administered in conjunction with other NSAIDs or
glucocorticosteroids. Concurrent administration of potential nephrotoxic drugs should
be avoided.
In cats, pre-treatment with anti-inflammatory substances may result in additional or
increased adverse effects and accordingly a treatment-free period with such
veterinary medicinal products should be observed for at least 24 hours before
commencement of treatment. The treatment-free period, however, should take into
account the pharmacological properties of the products used previously.